PYC Therapeutics Advances ADOA Clinical Trial with Dose Escalation Approval

PYC Therapeutics Limited ( (AU:PYC) ) has provided an announcement.

PYC Therapeutics has received approval from the Safety Review Committee to escalate the dose of its investigational drug candidate, PYC-001, in its clinical trial for Autosomal Dominant Optic Atrophy (ADOA). This approval allows the company to move from cohort 2 to cohort 3, increasing the dose from 10 to 30 micrograms per eye. The progression of this trial is a significant step towards establishing the safety and efficacy of PYC-001, with plans for further studies and a potential Phase 2/3 trial to support a New Drug Application.

The most recent analyst rating on (AU:PYC) stock is a Buy with a A$4.00 price target. To see the full list of analyst forecasts on PYC Therapeutics Limited stock, see the AU:PYC Stock Forecast page.

More about PYC Therapeutics Limited

PYC Therapeutics Limited is a clinical-stage biotechnology company focused on developing precision medicines for genetic diseases that currently have no treatment options. The company is working on creating first-in-class therapies, with a particular focus on conditions like Autosomal Dominant Optic Atrophy (ADOA), a blinding eye disease.

Average Trading Volume: 453,729

Technical Sentiment Signal: Buy

Current Market Cap: A$699.9M

See more data about PYC stock on TipRanks’ Stock Analysis page.